Meril Strengthens Its Position as a Leader in India’s Advancing MedTech Landscape

MUMBAI, MAHARASHTRA, 26 NOVEMBER, 2025 (GPN/ SACHIN MURDESHWAR 📞8108510506) — A 44-year-old male patient suffering from a severe heart condition, marked by extreme breathlessness, swollen feet, and an inability to carry out daily activities, has experienced a significant turnaround after undergoing Mumbai’s first Transcatheter Edge-to-Edge Repair (TEER) procedure. This minimally invasive cardiac therapy provides a vital alternative for patients who are too high-risk for open-heart surgery and is redefining treatment pathways for mitral valve disease in India.

Patient Background

The patient had been diagnosed with severe mitral regurgitation (MR), a condition in which the heart’s mitral valve does not close properly, causing blood to leak backward into the upper chamber. His symptoms had progressed to the point where routine activities such as walking short distances or climbing stairs had become highly restrictive.

Traditional treatments like open-heart surgery or heart transplant were not suitable because of his compromised heart function and associated risks. TEER—an advanced catheter-based therapy—was recommended as the safest and most effective option.

A Milestone in Advanced Cardiac Care

TEER offers a non-surgical solution for valve repair through a minimally invasive approach, significantly reducing procedural risks and shortening recovery time. The successful procedure was performed by Dr. Ankur Phatarpekar, Chief Cardiologist, HVS Symbiosis Hospital, along with other participants Dr Meghav Shah, Structural Interventional Cardiologist & Dr Gourish Shinde, HVS Symbiosis Hospital, Dadar, Mumbai marking a major advancement in the availability of high-end cardiac care in the city.

Successful Patient Outcome

Post-procedure, the patient showed substantial improvement. His breathlessness decreased, his mobility improved, and he is now able to resume daily activities—reflecting the effectiveness and patient-friendly nature of TEER therapy.

Expert Commentary

Sharing his insights, Dr. Ankur Phatarpekar said:

“TEER therapy is a crucial option for patients who cannot undergo open-heart surgery due to comorbidities or advanced heart failure. Severe mitral regurgitation, if left untreated, significantly increases mortality. TEER allows us to offer a safe, effective, and minimally invasive solution with markedly reduced risks. Introducing this therapy in Mumbai empowers us to treat high-risk patients who earlier had very limited options.”

Meril’s Role in Advancing India’s MedTech Landscape

The successful introduction of TEER in Mumbai underscores the transformative role Meril is playing in the country’s medtech sector. Through continuous innovation, development of advanced interventional cardiovascular solutions, and a strong commitment to research-driven engineering, Meril is enhancing India’s capability to deliver world-class, accessible, and patient-centered cardiac therapies.

By expanding access to cutting-edge cardiac interventions, Meril is strengthening India’s position on the global medtech map and helping ensure that sophisticated treatments reach patients across the country.

Meril Miclip is a minimally invasive heart valve repair device, also known as a Transcatheter Edge-to-Edge Repair (TEER) system, designed by Meril Life Sciences to treat severe mitral regurgitation. It is a catheter-based system used to clip together the leaky leaflets of the mitral valve to reduce blood leakage, offering a less invasive alternative to open-heart surgery for patients who are high-risk candidates.

How it works
Procedure: A small, flexible tube (catheter) is inserted into a blood vessel, typically in the leg, and guided to the heart.
Clipping: The MyClip device is used to grasp and join the edges of the mitral valve leaflets, similar to how a doctor might clip a piece of fabric to repair a seam.
Outcome: This procedure reduces the backward flow of blood, improving heart function.

Key Benefits and Features 

Minimally invasive: The procedure is performed through a catheter, avoiding the need for open-heart surgery.

Faster recovery: Patients can often go home within 3–5 days, with a relatively quick recovery period.

Targeted for high-risk patients: The MyClip system is intended for patients who are considered too frail for open-heart surgery, such as the elderly or those with other health conditions.

Indigenous Indian device: Meril Miclip is India’s first indigenous TEER system, positioning the country in the global landscape of structural heart innovation.